|
1
|
Metelitsa LS: Anti-tumor potential of
type-I NKT cells against CD1d-positive and CD1d-negative tumors in
humans. Clin Immunol. 140:119–129. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Godfrey DI, MacDonald HR, Kronenberg M,
Smyth MJ and Van Kaer L: NKT cells: What's in a name? Nat Rev
Immunol. 4:231–237. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
McEwen-Smith RM, Salio M and Cerundolo V:
The regulatory role of invariant NKT cells in tumor immunity.
Cancer Immunol Res. 3:425–435. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Crowe NY, Smyth MJ and Godfrey DI: A
critical role for natural killer T cells in immunosurveillance of
methylcholanthrene-induced sarcomas. J Exp Med. 196:119–127. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stewart TJ, Smyth MJ, Fernando GJ, Frazer
IH and Leggatt GR: Inhibition of early tumor growth requires
Jα18-positive (natural killer T) cells. Cancer Res. 63:3058–3060.
2003.PubMed/NCBI
|
|
6
|
Tagawa T, Wu L, Anraku M, Yun Z,
Rey-McIntyre K and de Perrot M: Antitumor impact of interferon-γ
producing CD1d-restricted NKT cells in murine malignant
mesothelioma. J Immunother. 36:391–339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bassiri H, Das R, Guan P, Barrett DM,
Brennan PJ, Banerjee PP, Wiener SJ, Orange JS, Brenner MB, Grupp SA
and Nichols KE: iNKT cell cytotoxic responses control T-lymphoma
growth in vitro and in vivo. Cancer Immunol Res. 2:59–69. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nur H, Rao L, Frassanito MA, De Raeve H,
Ribatti D, Mfopou JK, Van Valckenborgh E, De Bruyne E, Vacca A,
Vanderkerken K and Menu E: Stimulation of invariant natural killer
T cells by α-Galactosylceramide activates the JAK-STAT pathway in
endothelial cells and reduces angiogenesis in the 5T33 multiple
myeloma model. Br J Haematol. 167:651–663. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gebremeskel S, Clattenburg DR, Slauenwhite
D, Lobert L and Johnston B: Natural killer T cell activation
overcomes immunosuppression to enhance clearance of postsurgical
breast cancer metastasis in mice. Oncoimmunology. 4:e9955622015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Metelitsa LS, Wu HW, Wang H, Yang Y, Warsi
Z, Asgharzadeh S, Groshen S, Wilson SB and Seeger RC: Natural
killer T cells infiltrate neuroblastomas expressing the chemokine
CCL2. J Exp Med. 199:1213–1221. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tachibana T, Onodera H, Tsuruyama T, Mori
A, Nagayama S, Hiai H and Imamura M: Increased intratumor
Valpha24-positive natural killer T cells: A prognostic factor for
primary colorectal carcinomas. Clin Cancer Res. 11:7322–7327. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Molling JW, Langius JA, Langendijk JA,
Leemans CR, Bontkes HJ, van der Vliet HJ, von Blomberg BM, Scheper
RJ and van den Eertwegh AJ: Low levels of circulating invariant
natural killer T cells predict poor clinical outcome in patients
with head and neck squamous cell carcinoma. J Clin Oncol.
25:862–868. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qian X, Chen H, Wu X, Hu L, Huang Q and
Jin Y: Interleukin-17 acts as double-edged sword in anti-tumor
immunity and tumorigenesis. Cytokine. 89:34–44. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ye ZJ, Zhou Q, Gu YY, Qin SM, Ma WL, Xin
JB, Tao XN and Shi HZ: Generation and differentiation of
IL-17-producing CD4+ T cells in malignant pleural
effusion. J Immunol. 185:6348–6354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kryczek I, Banerjee M, Cheng P, Vatan L,
Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, et
al: Phenotype, distribution, generation, and functional and
clinical relevance of Th17 cells in the human tumor environments.
Blood. 114:1141–1149. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Greten TF, Zhao F, Gamrekelashvili J and
Korangy F: Human Th17 cells in patients with cancer: Friends or
foe? Oncoimmunology. 1:1438–1439. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan J, Liu XL, Xiao G, Li NL, Deng YN, Han
LZ, Yin LC, Ling LJ and Liu LX: Prevalence and clinical relevance
of T-helper cells, Th17 and Th1, in hepatitis B virus-related
hepatocellular carcinoma. PLoS One. 9:e960802014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He S, Fei M, Wu Y, Zheng D, Wan D, Wang L
and Li D: Distribution and clinical significance of Th17 cells in
the tumor microenvironment and peripheral blood of pancreatic
cancer patients. Int J Mol Sci. 12:7424–7437. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
De Simone V, Pallone F, Monteleone G and
Stolfi C: Role of Th17 cytokines in the control of colorectal
cancer. Oncoimmunology. 2:e266172013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen CJ, Yuan ZH, Liu YX and Hu GY:
Increased numbers of T helper 17 cells and the correlation with
clinicopathological characteristics in multiple myeloma. J Int Med
Res. 40:556–564. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Prabhala RH, Pelluru D, Fulciniti M,
Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson
PG, et al: Elevated IL-17 produced by TH17 cells promotes myeloma
cell growth and inhibits immune function in multiple myeloma.
Blood. 115:5385–5392. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bryant C, Suen H, Brown R, Yang S,
Favaloro J, Aklilu E, Gibson J, Ho PJ, Iland H, Fromm P, et al:
Long-term survival in multiple myeloma is associated with a
distinct immunological profile, which includes proliferative
cytotoxic T-cell clones and a favourable Treg/Th17 balance. Blood
Cancer J. 3:e1482013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jain P, Javdan M, Feger FK, Chiu PY, Sison
C, Damle RN, Bhuiya TA, Sen F, Abruzzo LV, Burger JA, et al: Th17
and non-Th17 interleukin-17-expressing cells in chronic lymphocytic
leukemia: Delineation, distribution, and clinical relevance.
Haematologica. 97:599–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hus I, Bojarska-Junak A, Chocholska S,
Tomczak W, Woś J, Dmoszyńska A and Roliński J: Th17/IL-17A might
play a protective role in chronic lymphocytic leukemia immunity.
PLoS One. 8:e780912013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lad DP, Varma S, Varma N, Sachdeva MU,
Bose P and Malhotra P: Regulatory T-cell and T-helper 17 balance in
chronic lymphocytic leukemia progression and autoimmune cytopenias.
Leuk Lymphoma. 56:2424–2428. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu T, Yu S, Liu Y, Yin C, Ye J, Liu Z, Ma
D and Ji C: Aberrant circulating Th17 cells in patients with B-cell
Non-Hodgkin's lymphoma. PLoS One. 11:e01480442016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY,
Xiao YS, Xu Y, Li YW and Tang ZY: Intratumoral balance of
regulatory and cytotoxic T cells is associated with prognosis of
hepatocellular carcinoma after resection. J Clin Oncol.
25:2586–2593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bates GJ, Fox SB, Han C, Leek RD, Garcia
JF, Harris AL and Banham AH: Quantification of regulatory T cells
enables the identification of high-risk breast cancer patients and
those at risk of late relapse. J Clin Oncol. 24:5373–5380. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Curiel TJ, Coukos G, Zou L, Alvarez X,
Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L,
Burow M, et al: Specific recruitment of regulatory T cells in
ovarian carcinoma fosters immune privilege and predicts reduced
survival. Nat Med. 10:942–949. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tosolini M, Kirilovsky A, Mlecnik B,
Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH,
Pagès F and Galon J: Clinical impact of different classes of
infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in
patients with colorectal cancer. Cancer Res. 71:1263–1271. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Salama P, Phillips M, Grieu F, Morris M,
Zeps N, Joseph D, Platell C and Iacopetta B: Tumor infiltrating
FOXP3+ T regulatory cells show strong prognostic
significance in colorectal cancer. J Clin Oncol. 27:186–192. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Badoual C, Hans S, Rodriguez J, Peyrard S,
Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P,
Fridman WH, et al: Prognostic value of tumor-infiltrating
CD4+ T-cell subpopulations in head and neck cancers.
Clin Cancer Res. 12:465–472. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tzankov A, Meier C, Hirschmann P, Went P,
Pileri SA and Dirnhofer S: Correlation of high numbers of
intratumoral FOXP3+ regulatory T cells with improved
survival in germinal center-like diffuse large B-cell lymphoma,
follicular lymphoma and classical Hodgkin's lymphoma.
Haematologica. 93:193–200. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Renukaradhya GJ, Khan MA, Vieira M, Du W,
Gervay-Hague J and Brutkiewicz RR: Type I NKT cells protect (and
type II NKT cells suppress) the host's innate antitumor immune
response to a B-cell lymphoma. Blood. 111:5637–5645. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li J, Sun W, Subrahmanyam PB, Page C,
Younger KM, Tiper IV, Frieman M, Kimball AS and Webb TJ: NKT cell
responses to B cell lymphoma. Med Sci (Basel). 2:82–97.
2014.PubMed/NCBI
|
|
36
|
Mattarollo SR, West AC, Steegh K, Duret H,
Paget C, Martin B, Matthews GM, Shortt J, Chesi M, Bergsagel PL, et
al: NKT cell adjuvant-based tumor vaccine for treatment of myc
oncogene-driven mouse B-cell lymphoma. Blood. 120:3019–3129. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Molling JW, Kölgen W, van der Vliet HJ,
Boomsma MF, Kruizenga H, Smorenburg CH, Molenkamp BG, Langendijk
JA, Leemans CR, von Blomberg BM, et al: Peripheral blood
IFN-gamma-secreting Valpha24+ Vbeta11+ NKT
cell numbers are decreased in cancer patients independent of tumor
type or tumor load. Int J Cancer. 116:87–93. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schwemmer B: Natural killer T cells in
patients with prostatic carcinoma. Urol Int. 71:146–149. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fujii S, Shimizu K, Klimek V, Geller MD,
Nimer SD and Dhodapkar MV: Severe and selective deficiency of
interferon-gamma-producing invariantnatural killer T cells in
patients with myelodysplastic syndromes. Br J Haematol.
122:617–622. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dhodapkar MV, Geller MD, Chang DH, Shimizu
K, Fujii S, Dhodapkar KM and Krasovsky J: A reversible defect in
natural killer T cell function characterizes the progression of
premalignant to malignant multiple myeloma. J Exp Med.
197:1667–1676. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yoneda K, Morii T, Nieda M, Tsukaguchi N,
Amano I, Tanaka H, Yagi H, Narita N and Kimura H: The peripheral
blood Valpha24+ NKT cell numbers decrease in patients
with haematopoietic malignancy. Leuk Res. 29:147–152. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bojarska-Junak A, Hus I, Sieklucka M,
Wąsik-Szczepanek E, Mazurkiewicz T, Polak P, Dmoszyńska A and
Roliński J: Natural killer-like T CD3+/CD16+
CD56+ cells in chronic lymphocytic leukemia:
Intracellular cytokine expression and relationship with clinical
outcome. Oncol Rep. 24:803–810. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gibson SE, Swerdlow SH and Felgar RE:
Natural killer cell subsets and natural killer-like T-cell
populations in benign and neoplastic B-cell proliferations vary
based on clinicopathologic features. Hum Pathol. 42:679–687. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hus I, Starosławska E, Bojarska-Junak A,
Dobrzyńska-Rutkowska A, Surdacka A, Wdowiak P, Wasiak M, Kusz M,
Twardosz A, Dmoszyńska A and Roliński J:
CD3+/CD16+ CD56+ cell numbers in
peripheral blood are correlated with higher tumor burden in
patients with diffuse large B-cell lymphoma. Folia Histochem
Cytobiol. 49:183–187. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE
and Ansell SM: Malignant B cells skew the balance of regulatory T
cells and Th17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res.
69:5522–5530. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Galand C, Donnou S, Crozet L, Brunet S,
Touitou V, Ouakrim H, Fridman WH, Sautès-Fridman C and Fisson S:
Th17 cells are involved in the local control of tumor progression
in primary intraocular lymphoma. PLoS One. 6:e246222011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Han Y, Wu J, Bi L, Xiong S, Gao S, Yin L,
Jiang L, Chen C, Yu K and Zhang S: Malignant B cells induce the
conversion of CD4+CD25− T cells to regulatory
T cells in B-cell non-Hodgkin lymphoma. PLoS One. 6:e286492011.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fozza C, Corda G, Virdis P, Contini S,
Barraqueddu F, Galleu A, Isoni A, Cossu A, Dore F, Careddu MG, et
al: Derangement of the T-cell repertoire in patients with B-cell
non-Hodgkin's lymphoma. Eur J Haematol. 94:298–309. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE
and Ansell SM: Attenuation of CD8(+) T-cell function by
CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma.
Cancer Res. 66:10145–10152. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yang ZZ, Novak AJ, Stenson MJ, Witzig TE
and Ansell SM: Intratumoral CD4+CD25+
regulatory T-cell-mediated suppression of infiltrating
CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood.
107:3639–3646. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Mittal S, Marshall NA, Duncan L, Culligan
DJ, Barker RN and Vickers MA: Local and systemic induction of
CD4+CD25+ regulatory T-cell population by
non-Hodgkin lymphoma. Blood. 111:5359–5370. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cao X, Cai SF, Fehniger TA, Song J,
Collins LI, Piwnica-Worms DR and Ley TJ: Granzyme B and perforin
are important for regulatory T cell-mediated suppression of tumor
clearance. Immunity. 27:635–646. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lindqvist CA, Christiansson LH, Thörn I,
Mangsbo S, Paul-Wetterberg G, Sundström C, Tötterman TH, Simonsson
B, Enblad G, Frisk P, et al: Both CD4+ FoxP3+
and CD4+ FoxP3−T cells from patients with
B-cell malignancy express cytolytic markers and kill autologous
leukaemic B cells in vitro. Immunology. 133:296–306. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Grygorowicz MA, Biernacka M, Bujko M,
Nowak E, Rymkiewicz G, Paszkiewicz-Kozik E, Borycka IS,
Bystydzienski Z, Walewski J and Markowicz S: Human regulatory T
cells suppress proliferation of B lymphoma cells. Leuk Lymphoma.
57:1903–1920. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Carreras J, Lopez-Guillermo A, Fox BC,
Colomo L, Martinez A, Roncador G, Montserrat E, Campo E and Banham
AH: High numbers of tumor-infiltrating FOXP3-positive regulatory T
cells are associated with improved overall survival in follicular
lymphoma. Blood. 108:2957–2964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE
and Ansell SM: CD70+ non-Hodgkin lymphoma B cells induce
Foxp3 expression and regulatory function in intratumoral
CD4+ CD25 T cells. Blood. 110:2537–2544. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ye J, Su X, Hsueh EC, Zhang Y, Koenig JM,
Hoft DF and Peng G: Human tumor-infiltrating TH17 cells have the
capacity to differentiate into IFN-g+ and
FOXP3+ T cells with potent suppressive function. Eur J
Immunol. 41:936–951. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Azuma T, Takahashi T, Kunisato A, Kitamura
T and Hirai H: Human CD4+ CD25+ regulatory T
cells suppress NKT cell functions. Cancer Res. 63:4516–4520.
2003.PubMed/NCBI
|
|
59
|
La Cava A, Van Kaer L and Fu-Dong-Shi:
CD4+CD25+ Tregs and NKT cells: Regulators
regulating regulators. Trends Immunol. 27:322–327. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Molling JW, Kölgen W, van der Vliet HJ,
Boomsma MF, Kruizenga H, Smorenburg CH, Molenkamp BG, Langendijk
JA, Leemans CR, von Blomberg BM, et al: Peripheral blood
IFN-gamma-secreting Valpha24+Vbeta11+ NKT
cell numbers are decreased in cancer patients independent of tumor
type or tumor load. Int J Cancer. 116:87–93. 2005. View Article : Google Scholar : PubMed/NCBI
|
